Abstract
Atrial fibrillation is by far the most frequent arrhythmia. It is particularly frequent in the elderly, in males, and in patients with heart disease. The prevalence of atrial fibrillation is 9.1% in men and women with cardiovascular disease (1). Data from the Framingham study (2) indicate that the overall incidence of developing atrial fibrillation was 529 new cases per year per 100 000 inhabitants aged 50–79 years (250 and 279 for paroxysmal and chronic forms, respectively). Given this high incidence, even if catheter ablation therapy were prescribed for a minority of drug-refractory patients, the total number of potential candidates for this treatment would be high. For example, during 1994 in our institutions radiofrequency catheter ablation of the atrioventricular junction and subsequent pacemaker implantation were performed in 6.4 patients per 100.000 inhabitants; that was only 1.2% of the patients with a new atrial fibrillation, but 18% of the total number of pacemakers implanted during the same period in that population. For comparison, it should be noted that the annual incidence of a new case of Wolff-Parkinson-White syndrome is 4 persons per 100 000 inhabitants (3), about one third of whom may perhaps benefit from radiofrequency therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Furberg C, Psaty B, Manolio T, Gardin J, Smith V, Rautaharju P (1994) Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Heart Study). Am J Cardiol 74: 236–241
Kannel W, Abbott R, Savage D, McNamara P (1983) Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J 106: 389–396
Munger T, Packer D, Hammill S, Feldman B, Bailey K, Ballard D, Holmes D, Gersh B (1993) A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation 87: 866–873
Brignole M, Menozzi C, Bottoni N, Bertulla A (1992) Comportamento della performance cardiaca nella fibrillazione atriale di diverse patogenesi. In: Rovelli F, De Vita C, Moreo A (eds) Cardiologia 1992. Librex, Milan, pp 443–451
Phillips E, Levine SA (1949) Auricular fibrillation without other evidence of heart disease: a cause of reversible heart failure. Am J Med 7: 479–489
Grogan M, Smith H, Gersh B, Wood D (1992) Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69: 1570–1573
Lemery R, Brugada P, Cheriex E, Wellens H (1987) Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am J Cardiol 60: 1406–1408
Peters KG, Kienzle MG (1988) Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 85: 242–244
Crijns H, Van gelder 1, Van Gilst W, Hillege H, Gosselink M, Lie K (1991) Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 68: 335–341
Zehender M, Hohnloser S, Muller B, Meinertz T, Jost H (1992) Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow’ up. J Am Coll Cardiol 19: 1054–1059
Hohnloser S (1994) Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation. PACE 17: 10191025
Antman E, Beamer A, Cantillon C, McGowan N, Friedman P (1990) Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 15: 698–707
Wong C, Lau C, Leung W, Cheng C (1990) Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol 66: 1212–1215
Beasley R, Smith D, McHaffie D (1985) Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J 290: 9–11
Lang R, Klein H, Weiss E, David D, Sareli P, Levy A, Guerrero J, Di Segni E, Kaplinsky E (1983) Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 83: 491–499
Rawles J, Metcalfe M, Jennings K (1990) Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 63: 225–227
Galun E, Flugelman M, Glikson M, Eliakim M (1991) Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 99: 1038–1040
Zarowitz B, Gheorghiade M (1992) Optimal heart rate control for patients with chronic atrial fibrillation: are pharmacologic choices truly changing ? Am Heart J 123: 1401–1403
Zoble R, Brewington J, Olukotun A, Gore R (1987) Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol 60: 39D - 45D
Roberts S, Diaz C, Nolan P, Salerno D, Stapczynski S, Zbrozek A, Ritz E, Bauman J, Vlasses P (1993) Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 72: 567–573
Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola S, Elkayam U (1986) Efficacy and safety of medium-and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 73: 316–324
Lewis R, Lakhani M, Moreland A, McDevitt D (1987) A comparison of verapamil and digoxin in the treatment of atrial fibrillation. Eur Heart J 8: 148–153
Lewis R, Laing E, Moreland T, Service E, McDevitt D (1988) A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J 9: 279–283
Lang R, Klein H, Di Segni E, Gefen J, Sareli P, Libhaber C, David D, Weiss E, Guerrero J, Kaplinsky E (1983) Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. Am Heart J 105: 820–824
Panidis I, Monganroth J, Baessler C (1983) Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 52: 1197–1201
Schwartz J, Keefe D, Kates D, Kirsten E, Harrison D (1982) Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 65: 1163–1170
Steinberg J, Katz R, Bren G, Buff L, Varghese J (1987) Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 9: 405–411
Maragno E, Santostasi G, Gaion R, Trento M, Grion A, Mi-raglia G, Dalla Volta S (1988) Low-and medium-dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J 116: 385–392
Lundstrom T, Ryden L (1990) Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 16: 86–90
Atwood E, Myers J, Sullivan M, Forbes S, Pewen W, Froelicher V (1988) Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 92: 20–25
DiBianco R, Monganroth J, Freitag J, Ronan J, Lindgren K, Donohue D, Larca L, Chadda K, Olukotun A (1984) Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 108: 1121–1127
Atwood E, Sullivan M, Forbes S, Myers J, Pewen W, Olson H, Froelicher V (1987) Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 10: 314–320
Brodsky M, Saini R, Bellinger R, Zoble R, Weiss R, Powers L (1994) Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. Am Heart J 127: 572–577
Channer K, Papouchado M, James M, Pitcher D, Russell Rees J (1987) Towards improved control of atrial fibrillation. Eur Heart J 8: 141–147
Packer DL, Bardy GH, Worley SJ, Smith MS, Cabb FR, Coleman E, Gallagher JJ, German LD (1986) Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 57: 563–570
Raeder E, Podrid P, Lown B (1985) Side effects and complications of amiodarone therapy. Am Heart J 109: 975–983
Souza O, Gursoy S, Simonis F, Steurer G, Andries E, Brugada P (1992) Right-sided versus left-sided radiofrequency ablation of the His bundle. PACE 15: 1454–1459
Trohman R, Simmons T, Moore S, Firstenberg M, Williams D, Maloney J (1992) Catheter ablation of the atrioventricular junction using radiofrequency energy and a bilateral cardiac approach. Am J Cardiol 70: 1438–1443
Twidale N, Sutton K, Bartlett L, Dooley A, Winstanley S, Heddle W, Hassam R, Koutsounis H (1993) Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. PACE 16: 1275–1284
Heinz G, Siostrzonek P, Kreiner G, Gossinger H (1992) Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug-refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 69: 489–492
Kalbfleisch S, Williamson B, Man C, Volperian V, Hummel J, Calkins H, Strickberger A, Langberg J, Morady F (1993) A randomized comparison of the right-and left-sided approaches to ablation of the atrioventricular junction. Am J Cardiol 72: 1406–1410
Menozzi C, Brignole M, Gianfranchi L, Lolli G, Oddone D, Gaggioli G, Bottoni N (1994) Radiofrequency catheter ablation and modulation of atrioventricular conduction in patients with atrial fibrillation. PACE 17: 2143–2149
Kay N, Epstein A, Dailey S, Plumb V (1993) Role of radiofrequency ablation in the management of supraventricular arrhythmias: experience in 760 consecutive patients. J Cardiovasc Electrophysiol 4: 371–389
Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, Lolli G, Oddone D, Gaggioli G (1994) Influence of atrio-ventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 74: 242–246
Rosenquist M, Lee M, Moulinier L, Springer M, Abbott J, Wu J, Langberg J, Griffin J, Scheinman M (1990) Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol 16: 1467–1474
Kay N, Bubien R, Epstein A, Plumb V (1988) Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 62: 741–744
Rodriguez LM, Smeets J, Xie B, de Chillou C, Cheriex E, Pieters F, metzger J, den Dulk K, Wellens H (1993) Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 72: 1137–1141
Hindricks G (1993) The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias. Eur Heart J 14: 1644–1653
Scheinman M (1994) Patterns of catheter ablation practice in the United States: results of the 1992 NASPE survey. PACE 17: 873–875
Raviele A, Delise P, Themistoclakis S, Coluccia S (1994) Complicanze dell’ablazione transcatetere. G Ital Cardini 24: 132–147
Olgin J, Scheinman M (1995) Catheter ablation of the atrioventricular node for treatment of supraventricular tachyarrhythmias. In: Zipes D and Jalife J (eds) Cardiac electrophysiology. From cell to bedside. Saunders, Philadelphia, pp 1453–1460
Evans T, Scheinman M, Zipes D, Benditt D, Breithardt G, Camm J, El-Sherif N, Fisher J, Fontaine G, Levy S, Pristosky E, Josephson M, Morady F, Ruskin J (1988) The percutaneous cardiac mapping and ablation registry: final summary of results. PACE 11: 1621–1626
Evans T (1991) Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction. Results of a prospective, international, multicenter study. Circulation 84: 1924–1937
O1gin J, Scheinman M (1993) Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol 21: 557–564
Levy S, Bru P, Aliot E, Attuel P, Barnay C, Clementy J, Ebagosti A, Fauchier JP, Fontaine G, Leclercq JF (1988) Longterm follow-up of atrioventricular junctional transcatheter electrical ablation. PACE 11: 1149–1153
Sadoul N, de Chillou C, Lamouri F, Simon JP, Reeb T, Pescariou S, Dodinot B, Aliot E (1994) Results, complications and long-term outcome of percutaneous ablation of atrioventricular conduction: a series of 85 cases. Arch Mal Coeur 87: 1453–1458
Carson P, Jonhson G, Dunkman B, Fletcher R, Farrell L, Cohn J (1993) The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT studies. Circulation 87: VI102–VI110
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Italia, Milano
About this paper
Cite this paper
Brignole, M., Menozzi, C., Gianfranchi, L. (1996). Control of Rapid Heart Rate in Patients with Atrial Fibrillation: Drugs or Ablation?. In: Raviele, A. (eds) Cardiac Arrhythmias 1995. Springer, Milano. https://doi.org/10.1007/978-88-470-2223-2_46
Download citation
DOI: https://doi.org/10.1007/978-88-470-2223-2_46
Publisher Name: Springer, Milano
Print ISBN: 978-3-540-75012-3
Online ISBN: 978-88-470-2223-2
eBook Packages: Springer Book Archive